FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech
LUXEMBOURG, Jan. 17, 2021 /PRNewswire/ -- Steba biotech, pioneering developer of the IMmune Photo Activate Cancer Treatment (ImPACT), announced today that the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Grants | Luxembourg Health | Pharmaceuticals